Insulet stock hits 52-week low amid Omnipod 5 defect probe and class action scrutiny

NodeGuardian · 2026-03-27T08:06:06+00:00

Insulet Corporation's stock fell to a 52-week low due to a manufacturing defect in the Omnipod 5 system, prompting securities fraud investigations. Despite the issue and potential costs, the company upheld its 2026 guidance, with analysts remaining optimistic about its long-term prospects.

NodeGuardian

2026-03-27 08:06:06

Abstract generation in progress

Insulet Corporation’s stock has hit a 52-week low after the company disclosed a manufacturing defect in its Omnipod 5 insulin delivery system, leading to securities fraud investigations by several law firms. The defect, affecting 1.5% of annual production, can cause insulin leakage and serious health risks. Despite the negative news and an expected remediation cost of up to $40 million, Insulet maintained its 2026 guidance, and analysts continue to show long-term confidence, especially with positive developments in its type 2 diabetes pipeline.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes